Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.
You may also be interested in...
Tysabri Backlash: GSK’s Phase II Multiple Sclerosis Drug On Clinical Hold
GSK drug is a dual alpha-4 integrin antagonist, the same mechanism of action as Tysabri. Biogen Idec/Elan suspended Tysabri marketing based on a safety signal. GSK had expected to file an NDA for ’699 in 2008.
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.